The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

Unless you’ve been living on another planet over the past few years, you have heard of and probably know several people that ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Weight loss drugs could soon be used to treat these seven other health conditions - Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen so ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...